Pharmacological neuromodulation with intracerebroventricular administration of anaerobic dopamine for Parkinson’s disease
Objective: To assess the continuous intracerebroventricular (i.c.v.) of A-dopamine in patients with a telemetry-controlled intra-abdominal pump system connected to a subcutaneous catheter implanted through the…24 Hour Maxillofacial Administration of Levodopa in a Parkinsons Patient -An Alternative Route of Administration in Parkinsons Disease
Objective: To assess tolerability, feasibility, safety and to assess outcome measures clinically as well as by serum levels over 24 hours, using the alternative maxillofacial…Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson’s Consortium
Objective: To advance the regulatory maturity of drug development tools to support the newly proposed integrated staging of Neuronal Synuclein Disease (NSD-ISS) with focus on…Boosting Clinical Trial Power in Parkinson’s Disease with AI-Generated Digital Twins
Objective: To evaluate the incorporation of prognostic digital twins to enhance traditional clinical trials in Parkinson’s Disease (PD) for disease modifying therapies. We assess the…Comparison of olfactory testing and PSG for detection of alpha-synuclein pathology in patients with dream enactment behavior or REM sleep behavior disorder
Objective: To compare the proportion of people with abnormal alpha-synuclein among groups with differing levels of certainty of REM sleep behavior disorder (RBD). Background: REM…Continuous Subcutaneous Apomorphine Infusion for Parkinson Disease Motor Fluctuations: Long-Term Data from the Ongoing InfusON Extension Study
Objective: Evaluate outcomes (up to 3 years) from the ongoing Extension Period of the InfusON study (NCT02339064) of continuous subcutaneous apomorphine infusion (CSAI). Background: Primary…Characterisation of the pharmacokinetic profile of amantadine in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of amantadine in the common marmoset (Callithrix jacchus). Background: Amantadine is currently approved for the treatment of L-3,4-dihydroxyphenylalanine…Neurotinib, a Brain Penetrant c-Abl Inhibitor, Prevents Activation and Phosphorylation of c-Abl Kinase and Alpha-Synuclein
Objective: Objective: To investigate Neurotinib, a newly developed allosteric c-Abl inhibitor, as a neuroprotective agent in a murine GBA1-associated Parkinson's disease (PD) model. Background: The…The impact of multimodal forms of art therapy on treatment outcomes and quality of life in Parkinson’s disease
Objective: Assessing the impact of art therapy on treatment outcomes and quality of life in Parkinson's disease (PD). Background: In addition to medical treatment, art…Exploring Non-Invasive Wearable Devices in Home Settings for Assessment and Treatment of the Duration of ON and OFF State and Freezing of Gait in Parkinson’s Disease: A Case Study.
Objective: To assess the effect of cueing with vibrotactile stimulation on the duration of ON and OFF state and freezing of gait (FOG) in patients…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 181
- Next Page »